Eton Pharmaceuticals, Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Unaudited financial figures are in thousands of dollars, except per-share amounts. Eton is a specialty pharmaceutical company focused on hospital injectables and pediatric rare-disease products. Biorphen, approved in October 2019 and launched in December 2019, was its only current product-sales revenue source.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $20 | $0 | $119 | $500 |
| Gross profit (loss) | $(8) | $0 | $(11) | $500 |
| Operating expenses | $4,530 | $3,349 | $13,408 | $11,403 |
| Operating loss | $(4,538) | $(3,349) | $(13,419) | $(10,903) |
| Net loss | $(4,730) | $(3,249) | $(13,779) | $(10,659) |
| Basic and diluted loss per share | $(0.23) | $(0.18) | $(0.70) | $(0.61) |
- Q2 gross margin was negative because cost of product sales ($28) exceeded sales ($20); six-month cost of sales was $130 against $119 revenue. There was no positive gross margin in 2020.
- Cash and cash equivalents were $10,270 at June 30, down from $12,066 at December 31, 2019. Current assets were $12,823 and current liabilities $2,739.
- Six-month operating cash use was $10,070, investing cash use $4, and financing cash provided $8,278. Financing included $7,756 net proceeds from common-stock sales and $361 in PPP loan proceeds. Cash declined by $1,796 during the period.
- Balance-sheet debt included $4,587 of SWK long-term debt, net of discount, plus a $361 PPP loan ($159 current and $202 long-term). The SWK loan’s gross principal was $5,000. The facility is secured by company assets and has a $3,000 minimum-cash requirement.
- Research and development expense was $1,609 in Q2 and $7,877 for six months; general and administrative expense was $2,921 and $5,531, respectively. No income tax expense was recorded.
Changes versus comparable periods
- Q2 revenue was only $20, entirely from Biorphen; six-month revenue fell to $119 from $500. The prior-year six-month amount reflected the sale of EM-100 product rights to Bausch, rather than recurring product sales.
- Net loss widened to $4,730 in Q2 from $3,249, and to $13,779 for six months from $10,659. Management attributed the six-month increase mainly to higher G&A, lower prior-year licensing revenue, and increased net interest expense.
- Q2 G&A increased $1,011 year over year, primarily due to Elcys patent-challenge legal costs, compensation, and Biorphen marketing and distribution. Six-month G&A rose $2,032.
- Six-month R&D was slightly lower year over year, but 2020 included $4,764 of Alkindi Sprinkle licensing expense; 2019 included $2,000 of Biorphen licensing expense. Q2 R&D increased $170.
- Six-month net interest expense increased $604, reflecting $388 of interest expense, mainly on SWK borrowings, and $216 less interest income. Stockholders’ equity decreased to $7,031 from $10,550 at year-end, while shares outstanding increased to 20,956,033 from 17,877,486.
Outlook, risks and notable items
- Management said existing cash and expected future revenues were expected to fund operating and capital needs for at least 12 months from issuance of the financial statements, based on anticipated Biorphen sales and spending management. It cautioned that cash could be used sooner and that additional financing may be needed; financing may not be available on acceptable terms. Failure to generate revenue or obtain financing could require operations to be scaled back or discontinued.
- COVID-19 disrupted hospital and surgical-center sales calls and product presentations, hindering Biorphen market adoption. Management expected sales and marketing efforts to remain adversely affected in 2020. The filing also warns of possible impacts on product demand, development timelines, clinical programs, and FDA review.
- Alkindi Sprinkle’s NDA was under FDA review, with a September 29, 2020 PDUFA date. Eton had paid Diurnal $3,500 cash and issued shares valued at $1,264 for initial licensing rights. EM-100’s FDA target action date had moved to September 15, 2020; Eton’s potential royalties depend on approval and other conditions.
- On August 11, 2020, after quarter-end, Eton amended its SWK credit facility: it agreed to draw $2,000, and the facility could increase from $10,000 to as much as $15,000 upon Alkindi Sprinkle FDA approval. The amendment also provides for future interest-rate reductions if performance metrics are achieved.
- Eton intends to pursue full or partial forgiveness of the $361 PPP loan; forgiveness was not assured. SWK covenants included minimum cash and limits on additional indebtedness, and the company was negotiating EBITDA and revenue covenant targets.
- Commitments include potential regulatory, approval, sales, royalty, and profit-sharing payments under product agreements. The filing reports no pending or threatened litigation expected to materially affect operations, but Eton had initiated a Paragraph IV patent challenge concerning Exela’s Elcys product.
Important facts for investors to verify
- Whether Biorphen sales recover from pandemic-related commercial disruptions and produce sustainable positive product economics.
- FDA decisions and timing for Alkindi Sprinkle, EM-100, and other pipeline candidates, and the associated milestone and financing implications.
- Cash burn, actual runway, SWK covenant compliance and draw availability, and the terms and status of the post-quarter $2,000 draw and facility amendment.
- Whether PPP loan forgiveness is obtained and whether future equity or debt financing is required, including potential dilution and financing restrictions.
- Actual Biorphen returns, chargebacks, discounts, and distribution fees compared with management’s revenue estimates, as these adjustments can affect reported sales.